Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2020-06-02 21:30:35
Reporting Period:
Accepted Time:
2020-06-02 21:30:35
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1621227 Adaptimmune Therapeutics Plc ADAP () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1388000 James Noble C/o Adaptimmune Therapeutics Plc,
60 Jubilee Avenue, Milton Park
Abingdon X0 OX14 4RX
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
American Depositary Shares Disposition 2020-05-29 500,000 $9.33 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.
  2. The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $9.02 to $10.13, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.
  3. The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 8,145,700 ordinary shares and share options covering an aggregate of 9,137,960 ordinary shares of the Issuer.